Skip to content
OpenCapital
Get started

Viking Therapeutics VKTX Q1 2026 earnings

Reported April 29, 2026 · After market close

Revenue-
EPS-$1.37Miss by $0.36
EPS estimate-$1.01

Next report

Oct 28, 2026 (in 3 months)
EPS estimate-$1.11

Financials

Q1 2026

Income statement

See full
Revenue-—
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$3.76B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Current ratio5.7×-38.5×

Versus estimates

Diluted EPS

Q2 2026-$1.10Beat by $0.11
Q1 2026-$1.37Miss by $0.36
Q4 2025-$1.38Miss by $0.49Q3 2025-$0.81Miss by $0.11Q2 2025-$0.58Miss by $0.14Q1 2025-$0.41Miss by $0.07

Ask the moment Viking Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Viking Therapeutics report Q1 2026 earnings?
Viking Therapeutics (VKTX) reported Q1 2026 earnings on April 29, 2026 after market close.
What were Viking Therapeutics's Q1 2026 revenue and EPS?
Viking Therapeutics reported revenue of - and eps of $-1.37 for Q1 2026.
Did Viking Therapeutics beat estimates in Q1 2026?
EPS missed the consensus estimate of $-1.01 by $0.36.
How did Viking Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 234.1% from $-0.41.
Where can I find Viking Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-191487) and the 10-Q periodic report (0001193125-26-193315) directly on SEC EDGAR. The filing index links above go to sec.gov.